AKVA group ASA (“AKVA”) is planning to release new shares to the stock market by means of a rights issue. AKVA has announced that it wishes to raise capital for investments in development of the company’s core products and core lines of business.
Terms of the Rights Issue
AKVA is releasing 8,611,434 new shares at a subscription price of NOK 11.00 per share. This is a fully underwritten rights issue, so any rights not taken up by shareholders will be purchased by the underwriters. Details subject to confirmation.
- Ex-date: 25th May 2011
- Record Date: 24th May 2011
- Ratio: 0.5 sub-rights for each share held.
- Call Price: NOK11.00
- Subscription period: 03/06/11 to 23/06/11
- Call date: 28th June 2011
After completion of the rights offering the share capital in AKVA will be NOK 25,834,303, divided on 25,834,303 shares, each having a par value of NOK 1.00.
AKVA Group Information
AKVA group develops technology for the global fish farming industry and is the only company in this market with global distribution.
Rolls Royce have announced that they are performing a company restructure today.
For each share held in Rolls-Royce Group plc (ordinary shares of 20p) shareholders will receive 1 new share of Rolls-Royce Holdings plc. in replacement.
- Effective Date: 23rd May 2011
- Old: Rolls-Royce Group ISIN GB0032836487
- New: Rolls-Royce Holdings ISIN GB00B63H8491
The value of your shares will be not affected by this change.
If you have any questions regarding this issue you can call the Market Operations team at the London Stock Exchange on 020 7797 4310 who will advise.
Note that this is not in related to the recent news that a Trent 900 Rolls-Royce engine failed on a Quantas A380 earlier this month. It is just a corporate restructure.
Rolls-Royce share price did dip today to 620p, down 15p. You can follow the latest share prices on the Rolls-Royce website: www.rolls-royce.com/investors/detailedshareprice/index.jsp
Commerzbank is hoping to raise EUR5.3 billion by means of a rights issue. Commerzbank plans to offer 2.44 billion new shares at a price of EUR2.18 each. This represents a 45 percent discount.
Shareholders will be able to subscribe to 10 new shares for every 11 held. The sub-rights will be trading from the 24th of May until 6th of June.
Commerzbank Rights Issue Terms and Dates
- Ex-date: 24/05/11
- Pay date: 07/07/11
- Ratio: 10 new for 11 held
- Call Price: EUR2.18
The purpose of the rights issue is to raise capital to help repay outstanding loans. Currently Commerzbank is around EUR14.3 billion in debt.
Commerzbank bought out Dresdner Bank 2 weeks before Lehman Bros collapsed. It received EUR18 billion bail out from th German government but still has huge debts to clear.
Royal Dutch Shell plc have announced their first quarter 2011 scrip dividend. They are giving shareholders the option to receive dividends in cash or in shares via a Scrip Dividend Programme.
- Dividend: Reference Share Price of $0.42 per A ordinary share (“A Share”) and B ordinary share (“B Share”).
- Reinvestment: Reference Share Price $34.986
Shareholders who do not join the Script Dividend Programme will continue to receive in cash any dividends declared by RDS.
Key Corporate Action Dates
- Ex-dividend date – May 11, 2011
- Record date – May 13, 2011
- Scrip reference share price announcement date -May 18, 2011
- Closing of scrip election and currency election – May 27, 2011
- Pounds sterling and euro equivalents announcement date – June 3, 2011
- Payment date – June 27, 2011
Learn more from Shell’s website: Royal Dutch Shell plc Scrip Dividend Programme
Intesa Sanpaolo SPA ordinary and savings shares have annouced the details of thie rights issue for May 2011:
Intesa Sanpaolo are paying an ordinary dividend and also running a rights issue to raise around EUR5 billion
Terms of Rights Issue:
For every 7 Intesa Sanpaolo SPA savings shares you are entitled to subscribe to 2 new shares.
- Issue date – 20 May 2011
- Effective date – 23 May 2011
- Expected pay date – 22 June 2011
- The call price is EUR1.369
- The price represents a discount of approximately 24% to the Theoretical Ex Right Price
- It closed trading on Friday 20th May at EUR1.75
Intesa Sanpaolo is a banking group resulting from the merger between Banca Intesa and Sanpaolo IMI.
IS Pharma and Sinclair Pharma are planning a Scheme of Arrangement and Reduction of Capital which is the method chosen to complete the merger of Sinclair Pharma plc with IS Pharma.
Effective date for the scheme will be 20th May 2011. On Monday 23rd May 2011 the trading of IS Pharma’s Shares on AIM will be cancelled.
- Effective Date of the Scheme – 20 May 2011
- Cancellation of IS Pharma Unapproved Options – 6.00 p.m. 20 May 2011
- Exercise of IS Pharma EMI Options – 6.00 p.m. 20 May 2011
- Issue of IS Pharma Shares to holders of IS Pharma EMI Options – 6.00 p.m. 20 May 2011
- Admission of Sinclair Pharma shares – 23 May 2011
- Cancellation of listing of Scheme Shares – 23 May 2011
- Latest date for despatch of cheques and certificates and settlement through CREST – Fourteen days from the Effective Date, ie. 03 Jun 2011
Terms of the Scheme of Arrangement
For each IS Pharma Share held you will receive 2.6868 New Sinclair Pharma Shares.
Grahame Cook, Chairman of Sinclair Pharma said:
“The Merger of Sinclair Pharma and IS Pharma will create significant benefits to both companies and their shareholders. There is good potential to increase revenues on a combined basis.”
The second of the AstraZeneca Takeover stories today is that they are apparently considering a bid for Shire Plc.
Shire is a biopharmaceutical company which specialises in treatments for attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) problems.
Shire have been performing well in the current climate. In their annual review they say:
“Shire visualized a tough future several years ago; it planned for it and continues to execute effectively. The results achieved this year once again demonstrate the wisdom of Shire’s business model.”
Shire closed today at 1,921.86p, down 14p.
Astrazeneca were also rumoured to be considering a takeover bid for Cubist Pharmaceuticals.
Before corporate actions are officially announced there are generally rumours circulating on the Internet. When I started out in corporate actions in 1997 such things never existed.
The latest rumour is that the FTSE100 pharmaceutical company AstraZeneca may be considering taking over Cubist Pharmaceuticals, a Massachusetts company.
The deal is related to Cubicin, a medicine which treats the superbug MRSA and some serious skin infections. This antibiotic had sales in the region of $600 last year and some analysts feel that this drug could turn out to be a golden egg.
Cubist won a patent dispute for Cubicin against Israels Teva which strengthens their position.
At the moment Cubist is certainly a very tempting target for a takeover as it has a potentially huge client base with proven sales already.
This would not be the first takeover of a company that specialising in vaccines. In 2007 AstraxZeneca acquired MedImmune at a cost of $15.2 billion to combine with its Cambridge Antibody Technology division.
If AstraZeneca was to successfully acquire Cubist Pharmaceuticals it will control a large share of the global vaccine market.
Today AstraZenaca stock price fell slightly to 3186.86p.
Michelin have announced details of their dividend reinvestment plan for 2010. The dividend is set at EUR1.78 with a reinvestment option.
Reinvestment price has been set at EUR56.5, a 10% discount to market value. Ex-date is 20th May 2011.
Current share price (at 17:39 on 05/20/2011) is EUR62.93.
The market default is cash, shareholders have until the 7th June 2011 to elect to reinvest (although asset management deadlines are likely to be sooner).
Pay date for the dividend or reinvested shares is 20th June 2011. News shares rank pari passu.
Find out more about Michelin in the Shareholders Corner of their website: www.michelin.com/shareholder-section
Banco Comercial Português (ISIN PTBCP0AMS055) have announced a subscription offer, approved at the AGM on the 18th April 2011.
The plan is to increase the share capital from EUR5,805,147,000 to EUR6,064,999,986 by issuing 721,813,850 new shares. Sub-rights will be issued and trade at EUR0.36 each.
Shareholders will are entitled to take up 0.1113585667 new shares for each sub-right held.
Final day for subscription is 9th June 2011. Pay date for the call is expected to be 14th June 2011.